...
首页> 外文期刊>International Journal of Pharmaceutical Sciences and Research >INFLUENCE OF VERAPAMIL ON PHARMACOKINETICS OF PIOGLITAZONE IN NORMAL AND DIABETIC RATS
【24h】

INFLUENCE OF VERAPAMIL ON PHARMACOKINETICS OF PIOGLITAZONE IN NORMAL AND DIABETIC RATS

机译:维拉帕米对正常和糖尿病大鼠吡格列酮药动学的影响。

获取原文
           

摘要

The study was undertaken to find out the pharmacokinetic drug interaction of verapamil on pioglitazone in normal and alloxan induced diabetic rats following single and multiple dose treatment. Human oral therapeutic doses of pioglitazone and verapamil were extrapolated to rats based on their body surface area. The serum pioglitazone concentrations were estimated by a sensitive reverse phase – high performance liquid chromatography (RP-HPLC) method. In single and multiple dose study, verapamil significantly increased the pioglitazone exposure (AUC, Cmax) and decreased its elimination by prolongation of t1/2 and mean residence time (MRT) with a relative decrease in clearance (CL). The effect is more significant in diabetic rats. In the present study a pharmacokinetic interaction between verapamil and pioglitazone was observed. The possible interaction may involve both P-glycoprotein and CYP enzymes. Investigating this type of interactions pre-clinically is helpful to avoid drug-drug interactions in actual clinical situation.
机译:进行该研究以找出维拉帕米对正常和四氧嘧啶诱导的糖尿病大鼠单剂量和多剂量治疗后吡格列酮的药代动力学药物相互作用。根据大鼠的体表面积将人口服吡格列酮和维拉帕米的治疗剂量外推至大鼠。血清吡格列酮浓度通过灵敏的反相高效液相色谱(RP-HPLC)方法估算。在单剂量和多剂量研究中,维拉帕米显着增加吡格列酮暴露(AUC,C max ),并通过延长t 1/2 和平均停留时间(MRT)来减少其消除),并且间隙(CL)相对减小。该作用在糖尿病大鼠中更为显着。在本研究中,观察到维拉帕米和吡格列酮之间存在药代动力学相互作用。可能的相互作用可能涉及P-糖蛋白和CYP酶。临床前研究此类相互作用有助于避免实际临床情况下的药物相互作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号